Strategic acquisition Fabric Genomics recently became a GeneDx company following a $51M acquisition, signaling strong validation and potential cross-sell opportunities with GeneDx’s existing diagnostics customers and global reach.

AI driven workflow The AI-powered interpretation platform supports whole genomes, exomes, and gene panels, offering a scalable solution for labs seeking faster, more accurate diagnoses and reduced turnaround times, ideal for outreach to hospital systems and national programs.

Clinical services In addition to software, Fabric Genomics provides CLIA- and CAP-accredited interpretation and reporting services, presenting a pathway for labs to scale capabilities quickly without expanding in-house genetics staff.

Collaborations Existing and recent partnerships with Galatea Bio, PlumCare, Oxford Nanopore, and DNAnexus illustrate a role as a platform integrator, suggesting opportunities to co-sell with partners and expand into newborn screening and PRS-based risk assessment.

Expansion potential Revenue is in the low-to-mid single-digit millions with substantial growth through integration with larger platforms, clinical partnerships, and expansion into genetic disease risk assays and broader clinical reporting capabilities.